Hanx Biopharmaceuticals repurchases 41,400 H-shares; treasury stock increases to 85,000

Bulletin Express04-08

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00 to HKD 32.12, translating into a volume-weighted average cost of HKD 31.87 per share and a total consideration of HKD 1.32 million.

Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.03% to 136.13 million, while treasury shares doubled to 85,000. The total issued share count remained unchanged at 136.22 million because the repurchased shares were retained as treasury stock and not cancelled.

The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative purchases under this mandate now stand at 85,000 shares, representing 0.06% of the company’s issued share base on the mandate date. In accordance with listing rules, Hanx Biopharmaceuticals is subject to a moratorium on new share issues or treasury-share sales until 08 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132152114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132152114","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals repurchases 41,400 H-shares; treasury stock increases to 85,000","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00 to HKD 32.12, translating into a volume-weighted average cost of HKD 31.87 per share and a total consideration of HKD 1.32 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.03% to 136.13 million, while treasury shares doubled to 85,000. The total issued share count remained unchanged at 136.22 million because the repurchased shares were retained as treasury stock and not cancelled.</p>\n<p>The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative purchases under this mandate now stand at 85,000 shares, representing 0.06% of the company’s issued share base on the mandate date. In accordance with listing rules, Hanx Biopharmaceuticals is subject to a moratorium on new share issues or treasury-share sales until 08 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals repurchases 41,400 H-shares; treasury stock increases to 85,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals repurchases 41,400 H-shares; treasury stock increases to 85,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00 to HKD 32.12, translating into a volume-weighted average cost of HKD 31.87 per share and a total consideration of HKD 1.32 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.03% to 136.13 million, while treasury shares doubled to 85,000. The total issued share count remained unchanged at 136.22 million because the repurchased shares were retained as treasury stock and not cancelled.</p>\n<p>The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative purchases under this mandate now stand at 85,000 shares, representing 0.06% of the company’s issued share base on the mandate date. In accordance with listing rules, Hanx Biopharmaceuticals is subject to a moratorium on new share issues or treasury-share sales until 08 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1132152114","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132152114","pubTimestamp":1775649836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药回购4.14万股H股；库存股增加至85,000股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 08 April 2026. The company repurchased 41,400 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 31.00 to HKD 32.12, translating into a volume-weighted average cost of HKD 31.87 per share and a total consideration of HKD 1.32 million.\nFollowing the transaction, issued shares outstanding (excluding treasury shares) fell by 0.03% to 136.13 million, while treasury shares doubled to 85,000. The total issued share count remained unchanged at 136.22 million because the repurchased shares were retained as treasury stock and not cancelled.\nThe buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative purchases under this mandate now stand at 85,000 shares, representing 0.06% of the company’s issued share base on the mandate date. In accordance with listing rules, Hanx Biopharmaceuticals is subject to a moratorium on new share issues or treasury-share sales until 08 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132152114","isCrawlerRequest":true}